Cenegermin for Optic Neuropathy

This trial tests a new treatment called cenegermin to determine its effectiveness for optic neuropathy, a condition where the optic nerve is damaged, affecting vision. The trial compares cenegermin to a placebo (a spray with no active medicine) in individuals recently diagnosed with a type of optic neuropathy called NAION. Participants may qualify if they have a NAION diagnosis in only one eye and noticed symptoms within the last two weeks. The goal is to assess whether cenegermin can improve vision and is safe to use. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment.

The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.

Research has shown that cenegermin is generally safe for people. In clinical trials, about 16% of participants experienced eye pain, the most common side effect. These side effects are usually mild and manageable. The FDA has already approved cenegermin for treating another eye condition, neurotrophic keratitis, which supports its safety. Overall, current evidence suggests the treatment is safe.¹²³⁴⁵

Most treatments for optic neuropathy focus on managing symptoms or slowing disease progression, such as with corticosteroids or surgery. However, cenegermin is unique because it targets nerve growth directly. It's a form of a naturally occurring protein that promotes nerve growth and survival, potentially offering a regenerative approach. Additionally, cenegermin is administered as a nasal spray, which is a novel and non-invasive delivery method compared to traditional treatments. Researchers are excited because this method might lead to faster and more effective nerve repair, offering hope for improved vision outcomes.

Studies have shown that cenegermin can improve vision in people with certain eye conditions. For example, one study found that most patients who used cenegermin experienced better vision that lasted for years. Research also indicates that cenegermin aids in healing the cornea, the clear front part of the eye, in many patients. Specifically, another study reported that 84.6% of patients with severe corneal problems healed after using cenegermin for 8 weeks. In this trial, participants will receive either cenegermin or a placebo vehicle spray. These findings suggest that cenegermin might support eye health and healing, potentially benefiting those with optic nerve issues.³⁴⁶⁷⁸